BSE Live
Nov 25, 11:05Prev. Close
888.90
Open Price
888.90
Bid Price (Qty.)
877.80 (662)
Offer Price (Qty.)
878.45 (32)
NSE Live
Nov 25, 11:05Prev. Close
889.30
Open Price
890.00
Bid Price (Qty.)
877.80 (6)
Offer Price (Qty.)
877.85 (5)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Dec 09 | Dec 08 | Dec 07 | Dec 06 | Dec 05 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 26.24 | 1.53 | -32.91 | 10.35 | 13.19 | |
| Diluted EPS (Rs.) | 26.24 | 1.53 | -32.91 | 10.35 | 13.19 | |
| Cash EPS (Rs.) | 31.88 | 6.25 | -27.52 | 15.05 | 16.76 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 214.14 | 82.34 | 55.94 | 89.67 | 82.56 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 214.14 | 82.34 | 55.94 | 89.67 | 82.56 | |
| Dividend / Share(Rs.) | 1.50 | 0.00 | 0.00 | 2.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 191.33 | 148.10 | 112.25 | 130.20 | 94.72 | |
| PBDIT/Share (Rs.) | 30.16 | 32.26 | -16.70 | 23.20 | 23.06 | |
| PBIT/Share (Rs.) | 24.52 | 27.55 | -22.10 | 18.51 | 19.49 | |
| PBT/Share (Rs.) | 11.04 | 12.75 | -33.72 | 11.94 | 13.93 | |
| Net Profit/Share (Rs.) | 26.24 | 1.53 | -32.91 | 10.35 | 13.19 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 15.76 | 21.78 | -14.87 | 17.82 | 24.34 | |
| PBIT Margin (%) | 12.81 | 18.60 | -19.68 | 14.21 | 20.58 | |
| PBT Margin (%) | 5.76 | 8.61 | -30.03 | 9.17 | 14.70 | |
| Net Profit Margin (%) | 13.71 | 1.03 | -29.32 | 7.95 | 13.92 | |
| Return on Networth / Equity (%) | 12.25 | 1.86 | -58.84 | 11.54 | 15.97 | |
| Return on Capital Employed (%) | 5.68 | 0.50 | -10.28 | 5.57 | 7.59 | |
| Return on Assets (%) | 4.13 | 0.34 | -7.21 | 3.97 | 5.89 | |
| Total Debt/Equity (X) | 1.43 | 3.33 | 5.43 | 1.06 | 1.10 | |
| Asset Turnover Ratio (%) | 30.17 | 33.82 | 24.61 | 49.99 | 42.34 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.00 | 0.94 | 1.66 | 1.58 | 2.16 | |
| Quick Ratio (X) | 0.86 | 0.78 | 1.51 | 1.33 | 1.87 | |
| Inventory Turnover Ratio (X) | 8.06 | 6.82 | 5.44 | 7.13 | 6.58 | |
| Dividend Payout Ratio (NP) (%) | 5.71 | 0.00 | 0.00 | 19.31 | 15.15 | |
| Dividend Payout Ratio (CP) (%) | 4.70 | 0.00 | 0.00 | 13.29 | 11.93 | |
| Earnings Retention Ratio (%) | 94.29 | 100.00 | 0.00 | 80.69 | 84.85 | |
| Cash Earnings Retention Ratio (%) | 95.30 | 100.00 | 0.00 | 86.71 | 88.07 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,211.96 | 1,488.49 | 1,975.73 | 1,645.89 | 1,374.27 | |
| EV/Net Operating Revenue (X) | 2.87 | 2.51 | 5.03 | 3.62 | 4.15 | |
| EV/EBITDA (X) | 18.24 | 11.52 | -33.80 | 20.29 | 17.05 | |
| MarketCap/Net Operating Revenue (X) | 1.25 | 0.60 | 2.52 | 2.81 | 3.28 | |
| Retention Ratios (%) | 94.28 | 100.00 | 0.00 | 80.68 | 84.84 | |
| Price/BV (X) | 1.12 | 1.09 | 5.05 | 4.08 | 3.76 | |
| Price/Net Operating Revenue | 1.25 | 0.60 | 2.52 | 2.81 | 3.28 | |
| Earnings Yield | 0.11 | 0.02 | -0.12 | 0.03 | 0.04 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016